Kornimate/medical-research-clean huggingface dataset:
family-school partnership intervention for early childhood education

Conditions: Autism Spectrum Disorder

Summary: strategies for creating and maintaining reciprocal partnerships between teachers and parents are considered essential elements of developmentally appropriate practice in early childhood education (ece). particularly for children who are high-risk for behavioral, developmental, or mental health problems, effective partnerships between family and preschool are essential for promoting optimal classroom participation and learning outcomes. the current study is an uncontrolled (pre-post) feasibility trial of family-school partnership intervention (fpsi). fspi was developed using stakeholder input, is delivered by existing preschool staff, and aims to promote development and reduce barriers to learning among children with pre-clinical social-communication delays. fspi integrates evidence-based practices (ebps) from education (7 ebps; national association for the education of young children) with clinical interventions for toddlers with autism spectrum disorder (asd) (12 ebps at the educator-parent level and 8 ebps at the parent-child level; naturalistic developmental behavioral interventions). data will be collected across 10 ece programs. at each participating ece program, research procedures will be completed during a single school year. selected ece programs will include public school, head start, and private preschool programs. participants include 20 non-teaching support staff (1-2 per program; e.g., director, principal, education-coordinator), 30 lead teachers (2-4 per program), and 60 children with social-communication deficits (two per teacher). data collection will focus on feasibility data (enrollment, attendance, attrition, data completion), observational measures of implementation fidelity (at the educator-parent and parent-child level), and mixed methods to evaluate educator and parent acceptability and satisfaction and identify implementation drivers/barriers. this research will prepare a large, multi-site hybrid trial to evaluate the effectiveness of fspi for promoting social-communication skills and kindergarten readiness, in addition to factors that mediate the relation between fspi delivery and fidelity (implementation drivers/barriers).


Eligibility criteria:
inclusion criteria: * currently attending classroom of participating preschool teacher. * nominated by teacher as child with elevated levels of social-communication challenges exclusion criteria: * n/a

Keywords: autism preschool naturalistic developmental behavioral intervention education parent
dural puncture epidural anesthesia versus traditional spinal anesthesia for rigid cystoscopy

Conditions: Dural Puncture Epidural Anesthesia; Spinal Anesthesia; Rigid Cystoscopy

Summary: the main objective of this study was to determine if the dural puncture epidural (dpe) anesthesia provides superior analgesia and better patient satisfaction when compared to traditional spinal anesthesia for rigid cystoscopy.

most urologic surgeries are performed in a narrow and limited space with the minimally invasive technique or cystoscope, and most patients undergoing urologic surgeries are elderly individuals with other diseases. cystoscopic evaluation of the lower urinary tract is a vital part of an office-based urologic practice. however, regular surveillance cystoscopy is a significant source of morbidity for patients, and therefore attempts have been made to minimize discomfort secondary to this procedure. spinal anesthesia is popular for endoscopic urological surgery because of early recognition of symptoms caused by overhydration, transurethral resection of prostate (turp) syndrome and bladder perforation. the dural puncture epidural (dpe) technique is a modification of the combined spinal epidural (cse) technique, where a dural perforation is created from a spinal needle but intrathecal medication administration is withheld. the dpe technique has been shown to improve caudal spread of analgesia compared with epidural (epl) technique without the side effects observed with the cse technique.

Eligibility criteria:
inclusion criteria: * age ≥18 years. * both sex. * american society of anesthesiology (asa) physical status i, ii, iii. * admitted for elective rigid cystoscopy. exclusion criteria: * refusal of patients. * body mass index (bmi) \> 35. * patients who have history of substance abuse. * patients with difficult communication. * contraindication to neuraxial anesthesia (e.g.; infection near the site of injection, coagulopathy or bleeding disorder). * patients with history of allergy to local anesthetics.
risk factors and outcomes of acute kidney injury in patients with diabetic ketoacidosis at sohag university hospital.

Conditions: Diabetic Ketoacidosis; Acute Kidney Injury

Summary: diabetic ketoacidosis (dka), a severe complication of diabetes mellitus (dm), is the leading cause of hospitalization, morbidity and mortality in patients with dm (1). dka is associated with hyperglycemic crises and featured by metabolic acidosis, the production of ketoacids, volume depletion, and electrolyte imbalance. due to glucose-induced osmotic polyuria and even emesis, volume depletion is a major cause of acute kidney injury (aki) in dka patients (2).


Eligibility criteria:
inclusion criteria: * patients will be included in this study aged \>18 years old after diagnosis of aki on top of diabetic ketoacidosis at sohag university hospital for all patients admitted during the period from may 2023 to may 2024 exclusion criteria: * chronic kidney disease

Keywords: dka aki
adebrelimab and concurrent radiochemotherapy as first-line treatment for extensive-stage small-cell lung cancer

Conditions: Small Cell Lung Carcinoma

Summary: patients with extensive-stage small-cell lung cancer (es-sclc) have poor prognosis, with limited treatment options. chemo-immunotherapy is the standard 1st-line therapy for patients with es-sclc.when 4 cycles of etoposide+carboplatin (ec) or etoposide+cisplatin(ep) chemotherapy combined with pd-l1 inhibitor are effective, guidelines recommend additional thoracic radiotherapy. in this study, the investigators bring radiotherapy forward, which means that after 2 cycles of ec chemotherapy plus adebrelimab, participants with response（pr/cr/sd）will receive concurrent radiotherapy and 2 cycles of ec chemotherapy plus adebrelimab, then maintenance therapy with adebrelimab （q3w）. the purpose of this study is to explore the safety and efficacy of adebrelimab combined with concurrent chemoradiotherapy in untreated participants with extensive-stage small cell lung cancer.

participants receive ec chemotherapy combined with adebrelimab for 2 cycles, and the efficacy will be evaluated. if the efficacy evaluation is sd/pr/cr, concurrent chemoradiotherapy combined with ec(2 cycles) + adebrelimab will be initiated. after concurrent chemoradiotherapy + adebrelimab, adebrelimab was maintained until pd or intolerance or for at most 2 years.

Eligibility criteria:
inclusion criteria: 1. aged 18-75 years; 2. histologically confirmed es-sclc (per the veterans administration lung study group \[valg\] staging system) ; 3. must sign a written informed consent form prior to any study specific procedures; 4. no prior treatment for es-sclc; 5. no more than 5 lesions (including metastases),and at least one measurable lesion that meets recist 1.1 evaluation criteria; 6. life expectancy more than 3 months; 7. ecog ps 0-1 exclusion criteria: 1. previous treatment with radiochemotherapy for limited-stage small cell lung cancer; 2. subjects who previously received systemic antitumor or immune checkpoint inhibitor therapy ; 3. active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs); replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment; 4. active brain metastases, leptomeningeal metastasis(untreated central nervous system (cns) metastases unless asymptomatic and lesion size\<1cm; 5. patients with spinal cord compression; 6. patients with multiple liver metastases(except isolated lesion and lesion size\<2cm); 7. uncontrollable third cavity effusion (e.g. a large amount of pleural effusion, ascites, or pericardial effusion, etc.) requiring repeated drainage, which was judged by the investigator to be unsuitable for study; 8. the investigator judges that there are any patients who endanger the patient's safety, interfere with the study assessment, and have poor compliance.

Keywords: es-sclc concurrent radiochemotherapy adebrelimab
the effect of different gingival biotypes on dimensional stability of free gingival graft

Conditions: Gingival Recession; Atrophy

Summary: the aim of this study is to compare the effect of mesial and distal adjacent gingival biotypes of the tooth / teeth region of free gingival graft (fgg) on the shrinkage ratio of graft at 6 months postoperatively.

the concept of gingival and periodontal phenotype was established as a result of clinical observation of changes in facial keratinized tissue width and thickness .it has been reported that gingival or periodontal diseases may develop more frequently in patients with thin gingival biotypes and that thick-flat biotype in implant restorations is important in achieving a successful aesthetic treatment outcome. free gingival graft (fgg) is a mucogingival surgical procedure that is successfully used in the presence of inadequate keratinized gingival width and gingival recession. it is thought that factors that may adversely affect the continuity of graft nutrition may be effective in graft shrinkage. these reasons can be listed as follows; graft thickness, traumatic surgical procedure, graft dehydration, and suturing procedure. there was no study investigating the effect of periodontal biotypes on graft contraction in the region adjacent to the fgg operation.

Eligibility criteria:
inclusion criteria: * in the mandibular incisor tooth / teeth, the attached keratinized gingival width is \<1 mm, * no periodontal surgery has been performed previously on the involved tooth. * in the absence of any systemic condition or illness (pregnancy, breastfeeding, mental retardation, diabetes, etc.) that may interfere with the patient's approval and dental treatment. * do not use any of the drug groups that may cause gingival overgrowth. exclusion criteria: * previous periodontal surgery in the operation area * restoration of the buccal surface of the tooth and no pathology in the apical region of the tooth. * in the presence of any systemic condition or illness (pregnancy, breastfeeding, mental retardation, diabetes, etc.) that may interfere with the patient's approval and dental treatment.

Keywords: gingival biotype of adjacent teeth free gingival graft shrinkage of graft
multimodal pain study in free flap patients

Conditions: Head and Neck Cancer; Analgesia

Summary: this study will be fashioned as a randomized, prospective study comparing pain management arm a and pain management arm b. arm a will have scheduled tylenol with opioids available as needed (prn) in the peri-operative period. arm b will undergo scheduled gabapentin, ketorolac and tylenol as well as the anesthesiology team managing regional nerve blocks, with opioids available prn in the peri-operative period. the amount of pain medication used by all patients will be recorded as well as pain scores documented on a pain scale (0-10 with 0 indicating no pain and 10 indicating worst pain ever) as well as abc pain scale throughout the patients' hospital stay. morphine equivalents for the opioids will be calculated for each arm while observing pain scores. then, the investigators will compare these two groups to see if there is a difference in opioid pain medication used. the study team's hypothesis is that the use of gabapentin, ketorolac, and tylenol in combination will significantly reduce (at least 30% of mean morphine equivalents - mme) the use of opioid medication for patients undergoing head and neck free flap reconstruction with similar to improved pain scores.


Eligibility criteria:
inclusion criteria: * patients over the age of 18 who are seen in the department of otolaryngology-head and neck surgery clinic. * patients with a new h\&n cancer diagnosis undergoing primary surgery (free flap) for their cancer treatment. exclusion criteria: * prior treatment for head and neck cancer. * planned treatment with primary radiation or chemoradiation for their head and neck cancer. * pregnant or lactating women. * patients with a history of consistent or regular opioid use for greater than six months used pre-operatively. * chronic gabapentin, pregabalin, and other non-opioid pain medication use pre-operatively. * diagnoses with fibromyalgia, anxiety disorder and other pain syndromes. * patients with documented history of kidney or liver disease. * patients with pre-operative lab values concerning for kidney/liver disease such as increased creatinine or liver function tests. * patients with a history of a serious gi bleed, cad, or history of ischemic stroke .
immunotherapy combined with capecitabine versus capecitabine monotherapy in advanced breast cancer

Conditions: Breast Cancer

Summary: the prognosis of advanced breast cancer does not improve much recently although varies of adjuvant drugs have been tried.dendritic cells co-cultured with cytokine-induced killer cells(dc-cik) immunotherapy has been proved to improve survival in several cancers, but its role in advanced breast cancer stains unclear. the purpose of this study is to evaluate the efficacy and safety of dc-cik immunotherapy combined with capecitabine versus capecitabine monotherapy for the treatment of advanced breast cancer.

1.400 patients with advanced breast cancer should be definitively diagnosis based on histopathology, according to the 7th american joint committee on cancer(ajcc) cancer staging manual. 2.all patients will be randomly divided into group a（dc-cik immunotherapy combined with capecitabine ) or group b（capecitabine monotherapy). 3.patients in group a will receive 4 cycles of dc-cik treatment (every 1 year) and capecitabine(continuous).patients in group b will receive only capecitabine monotherapy(continuous) . 4.the response is assessed using response evaluation criteria in solid tumor group (recist) guidelines.

Eligibility criteria:
inclusion criteria: * histologically confirmed with advanced breast cancer. * eastern cooperative oncology group (ecog) performance status was 0 - 2. * hemoglobin≥10.0g/dl, neutrophil count≥1.5×10\^9/l, platelet count≥75×10\^9/l; total bilirubin(tbil)≤1.5×uln; alkaline phosphatase(akp), aspartate aminotransferase(ast),alt≤2.5×uln(without metastasis of the liver), akp,ast,alt≤5×uln(with metastasis of the liver); bun≤1.5×uln, cr≤1.5×uln. * patient received 1-2 kinds of cytotoxic chemotherapy previously. * patient never received capecitabine or other oral fluorouracil. exclusion criteria: * patients who are suffering from serious organ dysfunction. * hiv positive or other immunodeficiency disease. * patients who had used long time or are using immunosuppressant drugs. * patients who had active infection. * patients who were allergic to fluorouracil. * pregnant or lactating women. * history of other malignancies. * other situations that the researchers considered unsuitable for this study.

Keywords: dc-cik breast cancer capecitabine
analysis of stroke rehabilitation outcomes

Conditions: Stroke

Summary: observe and describe the relationships between impairments and function, systematically characterize recovery patterns and examine short and long term rehabilitation outcomes. this project is purely observational, descriptive and non-experimental. n=273

this project involves an interdisciplinary stroke database of demographic variables and clinical measures collected during routine acute care, inpatient rehabilitation admission and discharge as well as follow up questionnaires at 6 month and 12 months to examine stroke recovery. our aim is to observe and describe the relationships between impairments and function, systematically characterize recovery patterns and examine short and long term rehabilitation outcomes. this project is purely observational, descriptive and non experimental. no rehabilitation interventions or treatment procedures are being introduced, modified or studied.

Eligibility criteria:
inclusion criteria: patients who have a confirmed primary diagnosis of cerebrovascular accident (cva) as per radiological assessment, met the criteria to be admitted onto baker 17 (the new york presbyterian inpatient rehabilitation unit), and were administered standardized assessments or rating scales as part of routine standard care will be included in the database. exclusion criteria: persons with stroke who could not be given standard assessments or rating scales (eg. due to fatigue, decreased attention span, global aphasia or refusal) will not be included in data analysis.
peritoneal dialysis versus haemodialysis

Conditions: Hemodialysis

Summary: study in order to quantify toxin removal during dialysis


Eligibility criteria:
inclusion criteria: * substudy 1: includes new starting dialysis patients on peritoneal dialysis pd or haemodialysis hd * substudy 2: stabile haemodialysis patients and peritoneal dialysis patients. patients will be matched for gender, time on dialysis, diabetes, renal function at the start of dialysis. * substudy 3: patients on capd (continuous ambulant pd) or ccpd (continuous cyclic pd).

Keywords: chronic renal insufficiency (patients under dialysis)
retrospective ci532 hearing performance

Conditions: Hearing Loss

Summary: the aim of this retrospective study is to collect and assess hearing performance data that have been measured by five clinics in germany as part of their clinical routine in recipients implanted with a commercial ci532.

speech understanding data in quiet and in noise and aided and unaided thresholds, medical history, anomalies in terms of electrode placement are collected through an ecrf. recipient's device characteristics are collected through cdx files. surgeon handling and usability of ci532 are collected through paper questionnaire. the retrospective study is aimed at collection of data for ci532 recipients who have routine hearing measures at pre-implant and post-implant intervals in their medical records. patients are approached for study participation by the caring clinician on a consecutive and voluntary basis and on condition of signing the patient informed consent.

Eligibility criteria:
inclusion criteria: * ability to conduct adult hearing performance test material * good german language skills to assess clinical hearing performance * ci532 recipients assessed via routine clinical measurements at pre implant, and post implant intervals with available data records in hospital files. * patients that have read, understood and signed the patient informed consent. exclusion criteria: * recipients that have participated in the cltd5446 study.

Keywords: moderate to profound sensorineural hearing loss
effect of fingolimod on the cardiac autonomic regulation in patients with multiple sclerosis

Conditions: Relapse-remitting Multiple Sclerosis

Summary: the purpose of this study is to study the effect of fingolimod on cardiac autonomic regulation in patients with relapse-remitting multiple sclerosis. this will be done by measuring heart rate variability from the 24-hour holter recording and myocardial ventricular repolarisation patterns from the 12-lead electrocardiogram tracings. the fingolimod treatment is prescribed according to the accepted drug label.

the study will include 30 relapse-remitting multiple sclerosis patients. assessments of heart rate variability and myocardial ventricular repolarisation pattern will be done 1) before fingolimod, 2) first day of fingolimod 3) after 3 months use and 4) after 12 months use of fingolimod.

Eligibility criteria:
inclusion criteria: * age 18 - 65 years * understands the proposed research and actions to be taken * the written informed consent has given * clinical indication to fingolimod-treatment exclusion criteria: * patient refuses * patient takes or has taken part in other clinical drug trial during the last month * no clinical indication to the use of fingolimod * contraindication to the use of fingolimod

Keywords: relapse-remitting multiple sclerosis heart rate variability fingolimod cardiac autonomic regulation
clinical performance of posterior indirect adhesive restorations

Conditions: Dental Caries; Endodontically Treated Teeth; Dental Restoration Failure of Marginal Integrity; Wear, Occlusal

Summary: clinical performance of indirect adhesive restorations - onlays, overlays- luted with light-cured composite resin will be evaluated.

indirect adhesive restorations are indicated in large class ii defects, replacement of large compromised existing restorations or endodontically treated teeth where cuspal protection is required. the need to perform adhesive restorations of posterior teeth is not only linked to esthetic purposes, but also have possibility of strengthening the remaining tooth structure. indirect technique decreases polymerization shrinkage, reduces microleakage and also improves the marginal seal when comparing direct resin composites. furthermore, it provides improved physical and mechanical properties, ideal occlusal morphology, more precise control of proximal contours and contacts. indirect adhesive restorations are classically delivered with an adhesive procedure including dual-cure cement. updated approaches now include the use of composite resins as luting agent. this study will be carried out as a prospective study, with assessment of the restorations after three years. pass 11 software was used to calculate the sample size. at least 77 indirect adhesive restorations will be included for this study. patients referred to istanbul okan university faculty of dentistry between 2016-2017 who had returned for the baseline recall and at least one year recall after the treatment will be invited for eligibility to participate in the study. 83 indirect adhesive restorations in at least 60 patients will be included. the patients who will not meet all the inclusion criteria will be excluded from the study. a signed informed consent form will be obtained from all patients before beginning the study. restorations will be evaluated clinically according to fdi world dental federation criteria. three main groups- esthetic, functional, biological properties- and their sub-categorizes of fdi world dental federation criteria will be scored on a scale of 1 to 5. statistical analysis will be performed using r (v.3.5.3) software and the sign.test function in the bsda package (p \<0.05).

Eligibility criteria:
inclusion criteria: * significant loss of dental hard tissue * endodontically treated teeth in posterior region * replacement of large compromised existing restoration * large class ii restoration * age of 18-60 years * good oral hygiene * presence of interproximal contact to at least one neighboring teeth • in occlusion with antagonist teeth * cavity preparation with at least one cuspal coverage exclusion criteria: * serious medical problems or allergies to substances and/or products to be used * severe periodontal problems * poor oral hygiene * direct pulp capping * presence of parafunctional behaviors * pregnant or breast feeding

Keywords: indirect restoration adhesive restoration cementation composite resin